What We Learned at ESMO GI 2025 About Botensilimab + Balstilimab | Fight CRC
Exciting data from the ESMO GI 2025 conference highlights a powerful new immunotherapy combo—Botensilimab + Balstilimab—that shows promising results.| Fight CRC
Exciting data from the ESMO GI 2025 conference highlights a powerful new immunotherapy combo—Botensilimab + Balstilimab—that shows promising results.| Fight CRC
This month we feature clinical trials for colorectal cancer patients with minimal residual disease (MRD) after curative-intent treatment. MRD| Fight CRC
